AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17329124 — intervention group
Group type: EXPERIMENTAL
Intervention: FM strength training protocol
Number of subjects: 20
Study 17329124 — intervention group
Group type: COMPARATOR
Intervention: CM strength training protocol
Number of subjects: 20
Study 16635085 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 microg, two inhalations bd (1280/36 microg/day)
Number of subjects: 456
Study 16635085 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol via separate inhalers
Number of subjects: 456
Study 16635085 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 456
Study 16635085 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 456
Study 16635085 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol
Number of subjects: 456
Study 16635085 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 456
Study 12559642 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analysis of a new drug for autoimmune disease
Number of subjects: 0
Study 11570837 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct contact group
Number of subjects: 986
Study 11570837 — intervention group
Group type: COMPARATOR
Intervention: PHT group
Number of subjects: 986
Study 11570837 — intervention group
Group type: COMPARATOR
Intervention: Program group
Number of subjects: 986
Study 9127653 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with pethidine
Number of subjects: 80
Study 9127653 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with fentanyl
Number of subjects: 80
Study 9127653 — intervention group
Group type: COMPARATOR
Intervention: PCIA with pethidine
Number of subjects: 80
Study 9127653 — intervention group
Group type: COMPARATOR
Intervention: PCIA with fentanyl
Number of subjects: 80
Study 7692189 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) at 10.5 +/- 1.2 micrograms/kg per day
Number of subjects: 23
Study 3092696 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (I)
Number of subjects: 70
Study 30558653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐implemented, goal‐directed, comfort algorithm
Number of subjects: 2800
Study 26277877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-indicated cerclage
Number of subjects: 301
Study 26277877 — intervention group
Group type: COMPARATOR
Intervention: Control (no cerclage)
Number of subjects: 301
Study 24256166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 μg Ni/week
Number of subjects: 141
Study 24256166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 22547727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted D2 distal gastrectomy
Number of subjects: 80
Study 22547727 — intervention group
Group type: COMPARATOR
Intervention: Open distal D2 gastrectomy
Number of subjects: 80
Study 20492055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster level models
Number of subjects: 0
Study 20492055 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patient level models
Number of subjects: 0
Study 20492055 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual level data models
Number of subjects: 0
Study 19193339 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 0
Study 19193339 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg
Number of subjects: 0
Study 16514812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril administration
Number of subjects: 94
Study 16514812 — intervention group
Group type: COMPARATOR
Intervention: Captopril administration
Number of subjects: 94
Study 11165527 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS to the supplementary motor area (SMA)
Number of subjects: 10
Study 11165527 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS to the supplementary motor area (SMA)
Number of subjects: 10
Study 9625099 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated AGP (> or = 1 g/L)
Number of subjects: 234
Study 9625099 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CRP (> or = 5 mg/L)
Number of subjects: 234
Study 9625099 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea and elevated AGP
Number of subjects: 234
Study 9625099 — intervention group
Group type: COMPARATOR
Intervention: Diarrhea only
Number of subjects: 234
Study 9625099 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness in the previous week with elevated CRP or AGP
Number of subjects: 234
Study 8170176 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin preoperatively
Number of subjects: 64
Study 8170176 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin followed by warfarin sodium
Number of subjects: 64
Study 8170176 — intervention group
Group type: COMPARATOR
Intervention: TE group (Thromboembolism)
Number of subjects: 64
Study 8170176 — intervention group
Group type: COMPARATOR
Intervention: Non-TE group (No Thromboembolism)
Number of subjects: 64
Study 3354812 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gauge Tuohy needle
Number of subjects: 685
Study 3354812 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge Tuohy needle
Number of subjects: 685
Study 1331724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatbran (60 g per day)
Number of subjects: 37
Study 1331724 — intervention group
Group type: COMPARATOR
Intervention: Wheatbran (equivalent amount of fibre)
Number of subjects: 37
Study 354331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluspirilene
Number of subjects: 50
Study 354331 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 50
Study 30597302 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week focused meditation training
Number of subjects: 0
Study 30597302 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 27743337 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention based on the Health Belief Model (HBM)
Number of subjects: 201
Study 23837502 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged implant placement
Number of subjects: 106
Study 23837502 — intervention group
Group type: COMPARATOR
Intervention: Transmucosal implant placement
Number of subjects: 106
Study 24409075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP) 80‐100 mg/m² iv on day 1 + leucovorin (CF) 100 mg/m² iv on days 1‐5 + 5‐fluorouracil (5‐FU) 500 mg/m² iv on days 1‐5
Number of subjects: 68
Study 24409075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (NDP)
Number of subjects: 68
Study 24409075 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (DDP)
Number of subjects: 68
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (the pill)
Number of subjects: 468
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 468
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 468
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch
Number of subjects: 468
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable
Number of subjects: 468
Study 22151509 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD
Number of subjects: 468
Study 19393409 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cautery followed by antiseptic cream for 4 weeks
Number of subjects: 109
Study 19393409 — intervention group
Group type: COMPARATOR
Intervention: Sham cautery followed by antiseptic cream for 4 weeks
Number of subjects: 109
Study 17370660 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescopic crowns on two endosseous implants
Number of subjects: 22
Study 17370660 — intervention group
Group type: COMPARATOR
Intervention: Telescopic crowns on maxillary canines
Number of subjects: 22
Study 15331202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oolong tea (1000 ml)
Number of subjects: 22
Study 15331202 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study 11439796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILMA) with lightwand
Number of subjects: 100
Study 11439796 — intervention group
Group type: COMPARATOR
Intervention: Intubating laryngeal mask airway (ILMA) alone
Number of subjects: 100
Study 9625830 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA index measurement in proliferating cells
Number of subjects: 0
Study 9625830 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA index measurement in cancer cells (gastric cancer, colon cancer, bile duct cancer, gallbladder cancer)
Number of subjects: 0
Study 9625830 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA index measurement in PBM patients with precancerous lesions
Number of subjects: 0
Study 8143398 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled marijuana smoke (1 marijuana cigarette containing 1.54% delta 9‐tetrahydrocannabinol)
Number of subjects: 20
Study 8143398 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 20
Study 8143398 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled marijuana smoke
Number of subjects: 20
Study 2895664 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual lormetazepam 2.5 mg
Number of subjects: 40
Study 2895664 — intervention group
Group type: COMPARATOR
Intervention: i.v. diazepam 10 mg
Number of subjects: 40
Study 30656849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol treatment
Number of subjects: 0
Study 30656849 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN inhibition
Number of subjects: 0
Study 30656849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol stimulation
Number of subjects: 0
Study 28939223 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 126
Study 28939223 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) + Whole-brain radiation therapy (WBRT)
Number of subjects: 126
Study 26319134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (4000 IE/day for 1 year)
Number of subjects: 124
Study 26319134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 23617135 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of move, adduction, rotation method
Number of subjects: 120
Study 23617135 — intervention group
Group type: COMPARATOR
Intervention: Traditional restoration methods with traction treatment
Number of subjects: 120
Study 21196073 — intervention group
Group type: EXPERIMENTAL
Intervention: Subinguinal microsurgical varicocelectomy (TA)
Number of subjects: 145
Study 21196073 — intervention group
Group type: COMPARATOR
Intervention: Observation (CA)
Number of subjects: 145
Study 18547177 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA 100,000 gel particles/mL filler with retreatment at 4.5 months
Number of subjects: 75
Study 18547177 — intervention group
Group type: EXPERIMENTAL
Intervention: NASHA 100,000 gel particles/mL filler with retreatment at 9 months
Number of subjects: 75
Study 16481296 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeus robot-assisted laparoscopic cholecystectomy
Number of subjects: 40
Study 16481296 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 40
Study 12930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashbulb memories
Number of subjects: 54
Study 12930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday memories
Number of subjects: 54
Study 12930476 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial visceral emotion ratings
Number of subjects: 54
Study 11380216 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 9778135 — intervention group
Group type: EXPERIMENTAL
Intervention: PALM‐diet
Number of subjects: 27
Study 9778135 — intervention group
Group type: COMPARATOR
Intervention: TRANS‐diet
Number of subjects: 27
Study 9778135 — intervention group
Group type: COMPARATOR
Intervention: PUFA‐diet
Number of subjects: 27
Study 7871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole treatment for 14 days
Number of subjects: 51
Study 7871380 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (bismuth subnitrate, oxytetracycline, metronidazole) for 2 weeks
Number of subjects: 51
Study 3370308 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg as aqueous solution
Number of subjects: 21
Study 3370308 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg as Tablet A (fast dissolution)
Number of subjects: 21
Study 3370308 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg as Tablet B (slow dissolution)
Number of subjects: 21
Study 3370308 — intervention group
Group type: COMPARATOR
Intervention: Furosemide tablets (both A and B)
Number of subjects: 21
Study 31477643 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (20 mg/kg)
Number of subjects: 100
Study 31477643 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone (20 mg/kg)
Number of subjects: 100
Study 28371433 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine alpha 1 microglobulin (α1m)
Number of subjects: 300
Study 28371433 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein‐1 (MCP‐1)
Number of subjects: 300
Study 28371433 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen type I (PINP)
Number of subjects: 300
Study 26860016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 90
Study 26860016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 90
Study 26860016 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution at a 'keep vein open' rate (Group E)
Number of subjects: 90
Study 23325481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride XR 60 mg once daily for 10 days plus metformin 500 mg twice daily for 3.5 days
Number of subjects: 44
Study 23325481 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg twice daily for 3.5 days
Number of subjects: 44
Study 23325481 — intervention group
Group type: COMPARATOR
Intervention: Trospium chloride XR 60 mg once daily for 10 days
Number of subjects: 44
Study 23325481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride XR and metformin coadministration
Number of subjects: 44
Study 21295937 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic statements by the interviewer
Number of subjects: 48
Study 19858754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Muscular Stabilization Techniques (DMST)
Number of subjects: 30
Study 19858754 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (electrotherapies and lumbar strengthening exercises)
Number of subjects: 30
Study 16916771 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning programme for general practitioners
Number of subjects: 187
Study 16916771 — intervention group
Group type: COMPARATOR
Intervention: Written guidelines (Control)
Number of subjects: 187
Study 15205566 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day vaginal micronized progesterone (group I)
Number of subjects: 252
Study 15205566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 100 microg/day + 600 mg/day vaginal micronized progesterone (group II)
Number of subjects: 252
Study 11502994 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) for 8 weeks
Number of subjects: 27
Study 11502994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day) for 8 weeks
Number of subjects: 27
Study 11502994 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 27
Study 11502994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 27
Study 11502994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 27
Study 9113812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg tid
Number of subjects: 123
Study 9113812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg tid
Number of subjects: 123
Study 9113812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 8256900 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (CS) therapy with methylprednisolone
Number of subjects: 48
Study 8256900 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 48
Study 8256900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 3839972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g sucralfate twice a day
Number of subjects: 80
Study 3839972 — intervention group
Group type: COMPARATOR
Intervention: 1 g sucralfate four times a day
Number of subjects: 80
Study 31867844 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus health expenditure questionnaire
Number of subjects: 100
Study 31867844 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus prevalence data application
Number of subjects: 100
Study 29775886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 59
Study 29775886 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 59
Study 26002952 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSQ (Athlete Sleep Screening Questionnaire)
Number of subjects: 60
Study 26002952 — intervention group
Group type: COMPARATOR
Intervention: Existing sleep-screening tools
Number of subjects: 60
Study 26002952 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSQ
Number of subjects: 60
Study 25085406 — intervention group
Group type: EXPERIMENTAL
Intervention: PharmD‐PCP MTM group
Number of subjects: 166
Study 25085406 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 166
Study 22645114 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with mitomycin C (0.5 mg/mL applied for 10 minutes)
Number of subjects: 76
Study 22645114 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic DCR without mitomycin C
Number of subjects: 76
Study 22645114 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with mitomycin C
Number of subjects: 76
Study 20728414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as part of a Traditional Chinese Medicine (TCM) package
Number of subjects: 0
Study 20728414 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as a monotherapy
Number of subjects: 0
Study 20728414 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0
Study 20728414 — intervention group
Group type: COMPARATOR
Intervention: Alarm therapy
Number of subjects: 0
Study 17919550 — intervention group
Group type: COMPARATOR
Intervention: PHX1149 single-dose (50 to 500 mg)
Number of subjects: 58
Study 17919550 — intervention group
Group type: COMPARATOR
Intervention: PHX1149 multiple-dose (50 to 400 mg QD for 13 days)
Number of subjects: 58
Study 17919550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 16053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (20 mg/day)
Number of subjects: 40
Study 16053461 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1-1.5 mg/day)
Number of subjects: 40
Study 16053461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12352513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formula with a protein/energy ratio of 2.2 g/100 kcal
Number of subjects: 0
Study 12352513 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with a protein/energy ratio of 1.8 g/100 kcal
Number of subjects: 0
Study 12352513 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study 10597955 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement 1.0 mg
Number of subjects: 8184
Study 10597955 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement 2.5 mg
Number of subjects: 8184
Study 10597955 — intervention group
Group type: COMPARATOR
Intervention: No folic acid supplement
Number of subjects: 8184
Study 10075964 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 18
Study 10075964 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 10 mg/kg/day
Number of subjects: 18
Study 10075964 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and UDCA
Number of subjects: 18
Study 1992600 — intervention group
Group type: EXPERIMENTAL
Intervention: nilutamide (Anandron), 100 mg t.i.d. with orchiectomy
Number of subjects: 203
Study 1992600 — intervention group
Group type: EXPERIMENTAL
Intervention: nilutamide (Anandron) plus orchiectomy
Number of subjects: 203
Study 1992600 — intervention group
Group type: COMPARATOR
Intervention: orchiectomy alone
Number of subjects: 203
Study 6188570 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 4
Study 30764655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 29383982 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 312
Study 29383982 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 312
Study 27004529 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue co-trimoxazole prophylaxis
Number of subjects: 969
Study 27004529 — intervention group
Group type: COMPARATOR
Intervention: Stop co-trimoxazole prophylaxis
Number of subjects: 969
Study 25574984 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg)
Number of subjects: 120
Study 25574984 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (0.4 mg/kg)
Number of subjects: 120
Study 25574984 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (3 ml)
Number of subjects: 120
Study 22491350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol administration (0.8 g/kg)
Number of subjects: 40
Study 22491350 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 40
Study 20389159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus, low-dose tacrolimus, and steroids (Group A)
Number of subjects: 24